Hillson R M, Smith R F, Dhar H, Moore R A, Hockaday T D
Diabetologia. 1983 Mar;24(3):210-2. doi: 10.1007/BF00250164.
Forty-three diabetic patients on maintenance chlorpropamide (100-750 mg daily) drank 0.2 ml/kg 90% ethanol after equilibration in a room controlled at 20 degrees C. Twenty-five patients had already noted marked alcohol flushing since starting chlorpropamide therapy (group A), while 13 had not observed this (group B). The remainder were teetotal or unsure of their reaction. Cheek temperature rise correlated with plasma chlorpropamide concentration (r = 0.6, p less than 0.001) in all patients and was inversely related to basal cheek temperature (r = -0.35, p less than 0.02). Plasma chlorpropamide correlated with daily chlorpropamide dose (r = 0.8, p less than 0.001) but not with basal cheek temperature. The correlation between chlorpropamide level and cheek temperature rise was strengthened on analysis of group A alone (r = 0.7, p less than 0.001) and absent in group B (r = 0.2, p greater than 0.3) who tended to have lower chlorpropamide levels and cheek temperature rise than group A.
43名正在接受氯磺丙脲维持治疗(每日100 - 750毫克)的糖尿病患者,在温度控制为20摄氏度的房间内平衡后,按0.2毫升/千克的剂量饮用了90%的乙醇。25名患者自开始氯磺丙脲治疗以来已出现明显的酒精潮红(A组),而13名患者未观察到这种情况(B组)。其余患者戒酒或不确定自己的反应。所有患者的脸颊温度升高与血浆氯磺丙脲浓度相关(r = 0.6,p < 0.001),且与基础脸颊温度呈负相关(r = -0.35,p < 0.02)。血浆氯磺丙脲与每日氯磺丙脲剂量相关(r = 0.8,p < 0.001),但与基础脸颊温度无关。单独分析A组时,氯磺丙脲水平与脸颊温度升高之间的相关性增强(r = 0.7,p < 0.001),而B组不存在这种相关性(r = 0.2,p > 0.3),B组的氯磺丙脲水平和脸颊温度升高往往低于A组。